Log in

NYSEAMERICAN:PLXProtalix Biotherapeutics Stock Price, Forecast & News

+0.03 (+0.84 %)
(As of 08/4/2020 04:00 PM ET)
Today's Range
Now: $3.60
50-Day Range N/A
52-Week Range
Now: $3.60
Volume71,201 shs
Average Volume177,931 shs
Market Capitalization$116.79 million
P/E RatioN/A
Dividend YieldN/A
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which has completed phase IIa clinical trials for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel.
Read More
Protalix Biotherapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Previous SymbolNYSEMKT:PLX



Sales & Book Value

Annual SalesN/A



Market Cap$116.79 million
Next Earnings Date8/10/2020 (Confirmed)
+0.03 (+0.84 %)
(As of 08/4/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PLX News and Ratings via Email

Sign-up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Protalix Biotherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Protalix Biotherapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Protalix Biotherapeutics

When is Protalix Biotherapeutics' next earnings date?

Protalix Biotherapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Protalix Biotherapeutics

How can I listen to Protalix Biotherapeutics' earnings call?

Protalix Biotherapeutics will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Protalix Biotherapeutics' earnings last quarter?

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) announced its quarterly earnings data on Monday, June, 1st. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.40. The firm had revenue of $21.65 million for the quarter, compared to the consensus estimate of $6.60 million. During the same period last year, the company posted ($0.50) earnings per share.
View Protalix Biotherapeutics' earnings history

When did Protalix Biotherapeutics' stock split? How did Protalix Biotherapeutics' stock split work?

Protalix Biotherapeutics's stock reverse split on the morning of Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of Protalix Biotherapeutics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for PLX?

1 brokerages have issued 12-month price targets for Protalix Biotherapeutics' shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate Protalix Biotherapeutics' share price to reach $11.00 in the next twelve months. This suggests a possible upside of 205.6% from the stock's current price.
View analysts' price targets for Protalix Biotherapeutics

Has Protalix Biotherapeutics been receiving favorable news coverage?

News coverage about PLX stock has been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Protalix Biotherapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the near term.
View the latest news about Protalix Biotherapeutics

Are investors shorting Protalix Biotherapeutics?

Protalix Biotherapeutics saw a decline in short interest in July. As of July 15th, there was short interest totaling 355,100 shares, a decline of 22.6% from the June 30th total of 458,600 shares. Based on an average trading volume of 231,500 shares, the days-to-cover ratio is presently 1.5 days. Approximately 1.5% of the company's shares are short sold.
View Protalix Biotherapeutics' Current Options Chain

Who are some of Protalix Biotherapeutics' key competitors?

What other stocks do shareholders of Protalix Biotherapeutics own?

Who are Protalix Biotherapeutics' key executives?

Protalix Biotherapeutics' management team includes the following people:
  • Mr. Moshe Manor, CEO, Pres & Director (Age 63)
  • Dr. Yoseph Shaaltiel, Founder and Exec. VP R&D (Age 65)
  • Mr. Yossi Maimon CPA, CPA, MBA, CFO, VP, Treasurer & Sec. (Age 48)
  • Mr. Yaron Naos, Sr. VP of Operations (Age 55)
  • Dr. Einat Brill-Almon, Sr. VP of Product Devel. (Age 59)

What is Protalix Biotherapeutics' stock symbol?

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

Who are Protalix Biotherapeutics' major shareholders?

Protalix Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Psagot Investment House Ltd. (1.45%).
View institutional ownership trends for Protalix Biotherapeutics

Which major investors are buying Protalix Biotherapeutics stock?

PLX stock was acquired by a variety of institutional investors in the last quarter, including Psagot Investment House Ltd..
View insider buying and selling activity for Protalix Biotherapeutics

How do I buy shares of Protalix Biotherapeutics?

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Protalix Biotherapeutics' stock price today?

One share of PLX stock can currently be purchased for approximately $3.60.

How big of a company is Protalix Biotherapeutics?

Protalix Biotherapeutics has a market capitalization of $116.79 million. Protalix Biotherapeutics employs 184 workers across the globe.

What is Protalix Biotherapeutics' official website?

The official website for Protalix Biotherapeutics is www.protalix.com.

How can I contact Protalix Biotherapeutics?

Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.